戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 etic/pharmacodynamic (PKPD) relationship for terfenadine.
2 d be observed only at high concentrations of terfenadine.
3 se of ("overlapping use") a prescription for terfenadine.
4 ocytes to compare the sensitivity of each to terfenadine.
5                 In this study, we found that terfenadine (1) increased both the fast and slow time co
6  Na(+)- and K(+)-free solutions; exposure to terfenadine (10(-9) to 5 x 10(-6) mol/L) resulted in a c
7 ine 118, sertraline 124, suloctidil 125, and terfenadine 127.
8                                              Terfenadine (5 micromol/L) induced phase 2 reentry in 6
9                            The antihistamine terfenadine and a gastrointestinal prokinetic drug, cisa
10                            Concurrent use of terfenadine and contraindicated drugs declined over the
11 anges in product labeling, concurrent use of terfenadine and contraindicated macrolide antibiotics an
12 on in the cardiac compartment in response to terfenadine and that response was modulated using a meta
13 e group affected channel block by cisapride, terfenadine, and MK-499.
14              Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazepine, alprazolam, tria
15 h tonic and use-dependent blocks of ICa,L by terfenadine at -40 mV were greater than that at -70 mV,
16  overall improvement in activity of the set, terfenadine-based analogues provide a novel structural c
17 ure-activity relationship studies yielded 84 terfenadine-based analogues with several modifications p
18                   These results suggest that terfenadine binds to L-type Ca2+ channels in inactivated
19 values compare well with values reported for terfenadine block of IKr and IKur currents in human atri
20 RG was 10 times more sensitive than Kv1.5 to terfenadine block.
21                                    We tested terfenadine carboxylate (fexofenadine) and terfenadine,
22                                              Terfenadine carboxylate, the major metabolite of terfena
23 ity of the antihistamine, since the clinical terfenadine concentrations in human plasma may reach the
24                            The antihistamine terfenadine decreased cell proliferation and reduced in
25 enadine carboxylate, the major metabolite of terfenadine, does not block either HERG or Kv1.5, which
26                        For the antihistamine terfenadine, drug-induced disruption of colonization res
27 ree chemically diverse ERG channel blockers (terfenadine, ErgToxin-1, and E-4031) abolished persisten
28 aloperidol, bufuralol, midazolam, clozapine, terfenadine, erlotinib, olanzapine, and moxifloxacin) in
29      We propose that the blocking of HERG by terfenadine explains the acquired long QT syndrome.
30 ere evaluated for organ-specific processing: terfenadine for pharmacokinetics (PK) and toxicity; trim
31  an average of 2.5 per 100 persons receiving terfenadine in 1990 to 0.4 per 100 persons during the fi
32           Among persons with paid claims for terfenadine in any given month, percentage with a prescr
33 model was developed to predict the effect of terfenadine in preclinical species.
34                                          The terfenadine-induced inhibition of ICa,L was not mediated
35                                          The terfenadine-induced tonic and use-dependent block and th
36 th the hypothesis that the buildup of parent terfenadine is the likely explanation for its cardiotoxi
37 ar wedge preparations with the use of either terfenadine or verapamil to inhibit INa and ICa or pinac
38         The histamine H1 receptor antagonist terfenadine prevented scratching and alloknesis evoked b
39                                              Terfenadine rescued the N470D mutation but blocked the c
40          Administration of the antihistamine terfenadine (Seldane) to patients may result in acquired
41 d terfenadine carboxylate (fexofenadine) and terfenadine, structurally similar drugs with markedly di
42 astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2
43  mechanisms underlying the cardiotoxicity of terfenadine, the effect of this antihistamine on L-type
44 ically competent liver module that converted terfenadine to fexofenadine.
45 roughput screen identified the antihistamine terfenadine to possess, previously unreported, antimicro
46 eactivating current was blocked by E-4031 or terfenadine (V(0.5,act) = -58.4 +/- 0.9 mV, V(0.5,inact)
47                                              Terfenadine, verapamil, and pinacidil each induced all-o
48 cin and cisapride, as well as cimetidine and terfenadine, were also reproduced.
49             The high-affinity interaction of terfenadine with the inactivated state of L-type Ca2+ ch